• FDA Confirms mFARS as Chief Measure in Phase 2 Trial of Omaveloxolone as Potential FA Therapy
  • Reata Raised $115.9M to Advance Pipeline Development, Including FA Therapy
  • Researchers Identify 2 Molecules That Boost Frataxin Levels in Friedreich’s Ataxia Animal Models
  • SIRT3 Protein Needed for Supplement to Aid Heart in Friedreich’s Ataxia, Study Suggests
  • MicroRNAs Levels in Blood May Diagnose Friedreich’s Ataxia and Those Patients with Heart Failure, Study Says
  • Researchers Create ‘Heart Cells in a Dish’ to Study FA Heart Disease
  • Increased Protein Modification Causes Heart Disease in Friedreich’s Ataxia Patients, Study Shows
  • Multiple Sclerosis Treatment Holds Promise for Friedreich’s Ataxia Patients, Studies Show
  • Brain May Alter Cerebral Functions to Compensate for Motor Deficits in Friedreich’s Ataxia
  • Part One of Reata’s MOXIe Trial for Friedreich’s Ataxia Shows Promising Results
  • Brain Structure Abnormalities in Late-onset Friedreich’s Ataxia Not Linked to Disease Features
  • Pfizer Seeks Patent Covering a Friedreich’s Ataxia Therapy That Resverlogix Has Already Developed